The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.

导出 LinkOut

翻译打印收藏纠错

第一作者： Maksim V,Baranov

第一单位： Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG Groningen, The Netherlands.

作者： Maksim V,Baranov ^[1] ; Frans,Bianchi ^[1] ; Geert,van den Bogaart ^[1]

作者单位： Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG Groningen, The Netherlands. ^[1] Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, The Netherlands. ^[2]

关键词 COVID-19 LAM-002A PIKfyve SARS-CoV-2 STA-5326 apilimod

主题词抗病毒药(Antiviral Agents);人类(Humans);腙类(Hydrazones);吗啉类(Morpholines);肽水解酶类(Peptide Hydrolases);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);蛋白酶抑制药(Protease Inhibitors);嘧啶类(Pyrimidines);丝氨酸内肽酶类(Serine Endopeptidases)

DOI 10.3390/cells10010030

PMID 33375410

发布时间 2022-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cells

2020年10卷1期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.

Cells

相似文献

Cells

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.

Cells

相似文献

Cells

相关期刊

检索历史清除